drugset / Trial / NCT07106762
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Timeline
- Start
- 2025-09-30
- Primary completion
- 2029-01-26
- Completion
- 2033-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Subject | Izalontamab Brengitecan | Unknown | — | — |